- Conditions
- Colon Polyps
- Interventions
- Clip closure
- Procedure
- Lead sponsor
- White River Junction Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 928 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- White River Junction, Vermont
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,957
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, EPCAM, RAD51C Gene Mutation
- Interventions
- CASCADE genetic screening
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Breast, Alzheimer Disease
- Interventions
- DECAD decision aid, Home safety guide
- Behavioral · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 75 Years and older · Female only
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 5
- States / cities
- Fort Wayne, Indiana • Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Education Counseling Session for PSA Screening, General Health Counseling Coaching
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 40 Years to 69 Years · Male only
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Geriatric Cancer Patients
- Interventions
- G8 Screening Tool
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Major Depression, Dysthymia
- Interventions
- ADAPt-C intervention
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
- Conditions
- Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
- Interventions
- AI model classification, DSOC endoscopist experts' classification
- Diagnostic Test
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 170 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Houston, Texas
- Conditions
- Colorectal Cancer, Colorectal Neoplasms
- Interventions
- Risk Information, Risk Information + Action
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 45 Years to 49 Years
- Enrollment
- 20,509 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Westwood, Los Angeles, California
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Cancer, Metastatic, Family Members
- Interventions
- Project Cornerstone
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Interventions
- Molecular Breast Imaging, Screening Mammography
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Screening
- Interventions
- Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 45 Years to 74 Years · Female only
- Enrollment
- 108,508 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2030
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more
- Conditions
- Colo-rectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 25,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2033
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Breast Cancer, Cervical Cancer
- Interventions
- Kin KeeperSM Cancer Prevention Intervention, Standard of care
- Behavioral · Other
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 21 Years to 70 Years · Female only
- Enrollment
- 516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
- Conditions
- Breast Cancer
- Interventions
- Stereoscopic Digital Mammography
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Female only
- Enrollment
- 1,467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Skin Neoplasms
- Interventions
- Patient activation and education (PAE), PAE plus physician activation (PAE + MD), PAE physician activation, plus teledermoscopy (PAE +MD +TD)
- Behavioral
- Lead sponsor
- Harvard School of Public Health (HSPH)
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Breast Cancer Screening
- Interventions
- Routine Screening Mammogram (3D + 2D), Routine Screening Mammogram (2D), No Screening Mammogram
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 586
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Omission of Radiation
- Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Breast Neoplasms
- Interventions
- RealRisks, BNAV
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- Taxotere, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2008
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Marginal Zone Lymphoma, MZL
- Interventions
- Venetoclax, Rituximab
- Drug
- Lead sponsor
- Gottfried von Keudell, MD PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Acute
- Interventions
- ACCESS-Leukemia
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts